Sasanlimab
Based on 1 Customer Validation
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.75%
- CAS No.: 2206792-50-7
- Masse moléculaire:146.438 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
Sasanlimab binds with high affinity to human and cynomolgus monkey PD-1, and shows no detectable binding to rat PD-1[2].
Sasanlimab (1 h) binds with high affinity to cell surface-expressed human and cynomolgus monkey PD-1 (EC50 values 51.04-222.55 pM across primary and transfected T cell models), shows minimal binding to mouse PD-1, and no detectable binding to rat PD-1[2].
Sasanlimab (serial dilutions, pmol/L range; 1 h) potently blocks the interaction of cell surface-expressed human and cynomolgus monkey PD-1 with their ligands PD-L1 and PD-L2, with IC50 values ranging from 839-1,058 pM[2].
Sasanlimab reverses PD-1/PD-L1-mediated inhibition of NFAT signaling in human PD-1-expressing Jurkat T cells, with an IC50 of 0.33 μg/mL[2].
Sasanlimab (10-5-101 μg/mL; 5 days) dose-dependently enhances human T-cell proliferation and production of IFNγ, TNFα, and IL2 in mixed lymphocyte reaction assays with PD-L1-expressing cells[2].
Sasanlimab (0.01-100 μg/mL; 1 h) dose-dependently enhances SEB-induced production of IFNγ, TNFα, and IL2 in cynomolgus monkey whole blood[2].
Sasanlimab does not mediate significant antibody-dependent cell-mediated cytotoxicity against activated human T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sasanlimab (10 mg/kg; intraperitoneal injection; 4 doses at days 10, 13, 16, and 23 after tumor inoculation) substantially delays the growth of established MC-38 colon adenocarcinoma tumors in human PD-1 knock-in mice without inducing toxicity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human PD-1 knock-in mice (GenOway; colon adenocarcinoma model via subcutaneous inoculation of 5×105 MC-38 cells)[2]
-
Dosage:10 mg/kg
-
Administration:intraperitoneal injection; 4 doses at days 10, 13, 16, and 23 after tumor inoculation
-
Result:Caused no aberrant body weight changes or toxicity signs.
Substantially delayed MC-38 tumor growth compared to controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 500 ng/mL Ionomycin (HY-13434) and 20 ng/mL PMA (HY-18739) co-stimulated 1X106 Jurkat cells (4h) with Sasanlimab ( red). Cells stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluo 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2206792-50-7
-
Appearance Liquid
-
Masse moléculaire 146.438 kDa
-
Color Colorless to light yellow
-
SMILES
[Sasanlimab]
-
Synonyms
PF-06801591
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Shore ND, et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31(8):2806-2814. [Content Brief]
[2]. Al-Khami AA, et al. Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020;19(10):2105-2116. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz